Evolent Health, INC. (EVH) — SEC Filings

Q: What are the key financial highlights for Evolent Health, INC.?

Key financial highlights for Evolent Health, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Evolent Health, INC.?

Key executives at Evolent Health, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Evolent Health, INC. stock?

Risk factors for Evolent Health, INC. (EVH) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Evolent Health, INC.?

Forward-looking statements and predictions from Evolent Health, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Evolent Health, INC.. Recent DEFA14A filing on Apr 24, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Evolent Health, INC. on SEC EDGAR

Overview

Evolent Health, INC. (EVH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: Evolent Health, Inc. filed an 8-K on December 8, 2025, reporting an "Other Event" that occurred on December 5, 2025. The filing does not provide specific details about the nature of this event, only that it is being reported under Item 8.01 of the 8-K form.

Sentiment Summary

Across 47 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 43 neutral. The dominant filing sentiment for Evolent Health, INC. is neutral.

Filing Type Overview

Evolent Health, INC. (EVH) has filed 1 DEFA14A, 26 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (47)

DEFA14A Filing — DEFA14A · Apr 24, 2026
Evolent Health Reports "Other Event" on 12/5 — 8-K · Dec 8, 2025 Risk: medium
Evolent Health, Inc. filed an 8-K on December 8, 2025, reporting an "Other Event" that occurred on December 5, 2025. The filing does not provide specific detail
Evolent Health Announces Board and Executive Compensation Changes — 8-K · Dec 2, 2025 Risk: low
Evolent Health, Inc. announced on December 1, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure
Evolent Health's Net Loss Widens to $150M Amid Revenue Decline — 10-Q · Nov 7, 2025 Risk: high
Evolent Health, Inc. (EVH) reported a significant increase in net loss attributable to common shareholders, reaching $150.27 million for the nine months ended S
8-K Filing — 8-K · Nov 6, 2025
Evolent Health Files 8-K on Sept 23 — 8-K · Sep 23, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on September 23, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclos
Evolent Health Reports Material Agreements & Equity Sales — 8-K · Aug 21, 2025 Risk: medium
Evolent Health, Inc. filed an 8-K on August 21, 2025, reporting on several key events that occurred on August 18, 2025. These include entering into a material d
Evolent Health Files 8-K — 8-K · Aug 19, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on August 19, 2025, reporting on events that occurred on August 18, 2025. The filing primarily concerns financial statements a
Evolent Health Files 8-K — 8-K · Aug 18, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on August 18, 2025, reporting other events and financial statements. The filing does not contain specific details on new event
Evolent Health's Q2 Net Loss Widens to $26.3M Amid Revenue Surge — 10-Q · Aug 11, 2025 Risk: high
Evolent Health, Inc. (EVH) reported a net loss of $26.3 million for the three months ended June 30, 2025, a significant increase from the $2.9 million net loss
Evolent Health Files 8-K on Operations and Financials — 8-K · Aug 7, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibit
Evolent Health Files 8-K for Material Agreement — 8-K · Jun 20, 2025 Risk: medium
Evolent Health, Inc. filed an 8-K on June 19, 2025, reporting the entry into a material definitive agreement. The filing also includes Regulation FD disclosures
Evolent Health Announces Board and Compensation Changes — 8-K · Jun 5, 2025 Risk: low
Evolent Health, Inc. announced on June 5, 2025, changes in its board of directors and executive compensation arrangements. The company also reported on matters
Evolent Health Files 8-K for Regulation FD Disclosure — 8-K · Jun 3, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on June 3, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of the di
Evolent Health Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: low
Evolent Health, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key financial data p
Evolent Health Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits.
Evolent Health Files DEF 14A Detailing 2024 Executive Compensation — DEF 14A · Apr 25, 2025 Risk: medium
Evolent Health, Inc. filed its DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including awa
Evolent Health Reports Officer Changes and Compensatory Arrangements — 8-K · Apr 22, 2025 Risk: medium
Evolent Health, Inc. filed an 8-K on April 22, 2025, reporting on events that occurred on April 16, 2025. The filing primarily concerns the departure of directo
Evolent Health Files 2024 10-K — 10-K · Feb 21, 2025 Risk: medium
Evolent Health, Inc. filed its 2024 10-K on February 21, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware, is
Evolent Health Files 8-K on Financials — 8-K · Feb 20, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on February 20, 2025, reporting on its financial condition and results of operations. The filing includes financial statements
Evolent Health Reports Key Corporate Changes and Agreements — 8-K · Feb 4, 2025 Risk: medium
Evolent Health, Inc. announced on February 3, 2025, several key events including the entry into a material definitive agreement, the departure of directors or c
Evolent Health Reports New Financial Obligation — 8-K · Jan 30, 2025 Risk: medium
Evolent Health, Inc. filed an 8-K on January 30, 2025, reporting the creation of a direct financial obligation or an obligation under an off-balance sheet arran
Evolent Health Files 8-K — 8-K · Jan 13, 2025 Risk: low
Evolent Health, Inc. filed an 8-K on January 13, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain s
Evolent Health Enters Material Definitive Agreement — 8-K · Dec 11, 2024 Risk: medium
Evolent Health, Inc. entered into a material definitive agreement on December 6, 2024. This filing also indicates the creation of a direct financial obligation
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
Evolent Health Files Q3 2024 10-Q Report — 10-Q · Nov 8, 2024 Risk: medium
Evolent Health, Inc. filed its Q3 2024 10-Q report on November 8, 2024, covering the period ending September 30, 2024. The filing details the company's financia
Evolent Health Files 8-K for Financial Reporting — 8-K · Nov 7, 2024 Risk: low
Evolent Health, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition, as well as to file financial statements a
Evolent Health Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
Evolent Health, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter
Evolent Health Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
Evolent Health, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibit
SC 13G/A Filing — SC 13G/A · Aug 7, 2024
SC 13G/A Filing — SC 13G/A · Jul 10, 2024
SC 13G Filing — SC 13G · Jun 17, 2024
Evolent Health Files 8-K on Security Holder Vote — 8-K · Jun 11, 2024 Risk: low
Evolent Health, Inc. filed an 8-K on June 11, 2024, reporting on a matter submitted to a vote of security holders on June 6, 2024. The filing details the compan
Evolent Health Files 8-K — 8-K · Jun 4, 2024 Risk: low
Evolent Health, Inc. filed an 8-K on June 4, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other even
Evolent Health, Inc. Files 10-Q for Q1 2024 — 10-Q · May 10, 2024 Risk: medium
Evolent Health, Inc. (EVH) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Evolent Health, Inc. filed its 10-Q report for the period ending March
Evolent Health Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
Evolent Health, Inc. filed an 8-K on May 9, 2024, reporting on its financial condition and results of operations. The filing includes financial statements and e
Evolent Health Files Definitive Proxy Statement — DEF 14A · Apr 26, 2024 Risk:
Evolent Health, Inc. (EVH) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Evolent Health, Inc. filed a Definitive Proxy Statement on April 26
SC 13G/A Filing — SC 13G/A · Apr 9, 2024
Evolent Health, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 23, 2024 Risk: low
Evolent Health, Inc. (EVH) filed a Annual Report (10-K) with the SEC on February 23, 2024. Evolent Health, Inc. filed its annual report on Form 10-K for the fis
Evolent Health Files 8-K on Financial Condition — 8-K · Feb 22, 2024 Risk: low
Evolent Health, Inc. filed an 8-K on February 22, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number 001-37
Evolent Health Reports Officer/Director Changes & Compensation — 8-K · Feb 14, 2024 Risk: medium
Evolent Health, Inc. filed an 8-K on February 14, 2024, reporting events that occurred on February 12, 2024. The filing indicates changes related to the departu
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
FMR LLC & Abigail Johnson Maintain 11.213% Stake in Evolent Health — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have filed an amended SC 13G/A for Evolent Health, Inc. (EVH). As of February 9,
Wellington Management Discloses 8.0% Stake in Evolent Health — SC 13G · Feb 8, 2024 Risk: low
Wellington Management Group LLP, a Massachusetts-based investment firm, filed an SC 13G on February 8, 2024, disclosing its ownership of Evolent Health, Inc. co
BlackRock Amends Evolent Health Stake, Maintains Passive Position — SC 13G/A · Jan 26, 2024
BlackRock, Inc. filed an amended Schedule 13G/A on January 26, 2024, indicating its ownership of Class A Common Stock in Evolent Health, Inc. as of December 31,
JPMorgan Amends Evolent Health Stake (SC 13G/A, Amendment 07) — SC 13G/A · Jan 18, 2024
JPMorgan Chase & Co. filed an amended Schedule 13G/A on January 18, 2024, indicating a change in their beneficial ownership of Evolent Health, Inc.'s Class A Co
Evolent Health Files 8-K on Operations & Financial Condition — 8-K · Jan 8, 2024
Evolent Health, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as Regulation FD disclosure and fi

Risk Profile

Risk Assessment: Of EVH's 35 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Evolent Health, INC.'s most recent 10-Q filing (Nov 7, 2025):

Revenue: $1,407,510,000
Net Income: -$150,270,000
EPS: Not Disclosed
Debt-to-Equity: 1.91
Cash Position: $116,650,000
Operating Margin: Not Disclosed
Total Assets: $2,453,459,000
Total Debt: $1,060,000,000

Key Executives

Seth Blackley
Frank Williams
Abigail P. Johnson
Massachusetts
December 29, 2023
February 8, 2024

Industry Context

Evolent Health operates in the complex healthcare services sector, focusing on managing care for individuals with chronic and complex conditions. The industry is characterized by evolving regulatory landscapes, pressure to reduce costs, and a shift towards value-based care models. Companies like Evolent Health aim to bridge the gap between payers and providers, leveraging technology and data to improve patient outcomes and operational efficiency.

Top Tags

sec-filing (7) · 8-K (6) · financial-condition (5) · financials (5) · disclosure (4) · material-agreement (4) · financial-reporting (4) · 10-Q (4) · corporate-governance (4) · institutional-ownership (4)

Key Numbers

Net Loss: $150.27M — Increased 139% for the nine months ended September 30, 2025, from $62.84M in 2024.
Revenue: $1.41B — Decreased 26.2% for the nine months ended September 30, 2025, from $1.91B in 2024.
Long-term Debt: $1.05B — Increased from $490.52M at December 31, 2024, to $1.05B at September 30, 2025.
Loss on Option Exercise: $52.54M — A new significant expense for the nine months ended September 30, 2025.
Assets Held for Sale - Noncurrent: $73.67M — Indicates potential divestitures as of September 30, 2025.
Cash and Cash Equivalents: $116.65M — Slight increase from $104.20M at December 31, 2024.
Net Loss Increase: 139% — Percentage increase in net loss attributable to common shareholders year-over-year for the nine-month period.
Revenue Decrease: 26.2% — Percentage decrease in revenue year-over-year for the nine-month period.
SG&A Expenses: $105.7M — Increased from $65.4M in Q2 2024, contributing to wider net loss.
Revenue Growth: 86% — Year-over-year increase in Q2 2025 revenue, demonstrating market expansion.
Contingent Consideration Change: $2.6M — Additional liability impacting net loss in Q2 2025.
SEC File Number: 001-37415 — Identifies Evolent Health's filing with the SEC.
EIN: 32-0454912 — Employer Identification Number for Evolent Health.
Reporting Period End Date: 2025-03-31 — Indicates the end of the fiscal quarter covered by the report.
Filing Date: 2025-05-09 — The date Evolent Health, Inc. submitted this 10-Q to the SEC.

Forward-Looking Statements

{"claim":"FMR LLC will maintain a significant ownership stake in Evolent Health, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
{"claim":"Other institutional investors may increase their positions in Evolent Health, Inc.","entity":"Evolent Health, Inc.","targetDate":"Within 6 months","confidence":"medium"}

Related Companies

EVLT

Frequently Asked Questions

What are the latest SEC filings for Evolent Health, INC. (EVH)?

Evolent Health, INC. has 47 recent SEC filings from Jan 2024 to Apr 2026, including 26 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of EVH filings?

Across 47 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 43 neutral. The dominant sentiment is neutral.

Where can I find Evolent Health, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Evolent Health, INC. (EVH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Evolent Health, INC.?

Key financial highlights from Evolent Health, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for EVH?

The investment thesis for EVH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Evolent Health, INC.?

Key executives identified across Evolent Health, INC.'s filings include Seth Blackley, Frank Williams, Abigail P. Johnson, Massachusetts, December 29, 2023 and 1 others.

What are the main risk factors for Evolent Health, INC. stock?

Of EVH's 35 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 20 low-risk.

What are recent predictions and forward guidance from Evolent Health, INC.?

Recent forward-looking statements from Evolent Health, INC. include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in Evolent Health, Inc. for the foreseeable future.","enti and 1 other predictions.